降脂药物与尿酸和痛风结局之间的关联:孟德尔的随机化研究
Min Liu1, Na Yin2, Yuhang Zhu1
1Department of Orthopaedics, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Frontiers in endocrinology
|February 10, 2025
概括
遗传分析表明,向HMGCR的降脂药物可能会增加痛风风险,而PCSK9抑制剂可能会提高尿酸水平. 这项研究探讨了这些药物和痛风之间的有争议的联系.
科学领域:
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 脂质代谢是尿酸平衡和痛风发展的组成部分.
- 观察性研究表明,降脂药物与尿酸/痛风之间存在关联,但研究结果仍有争议.
- 调查遗传联系为理解因果关系提供了一个强有力的方法.
研究的目的:
- 通过遗传学研究降脂药物标与尿酸/痛风风险之间的关联.
- 区分不同类型的降脂药物对尿酸盐和痛风的影响.
主要方法:
- 使用孟德尔随机化 (MR) 方法,用于降脂药物标的基因代理 (HMGCR,PCSK9,NPC1L1).
- 采用逆方差加权 (IVW) 和基于总结数据的门德尔随机化 (SMR) 方法.
- 进行了敏感性分析,包括MR-Egger和leave-one-out以确保结果的有效性.
主要成果:
- HMGCR 抑制剂与痛风风险增加存在遗传相关性 (IVW:OR 1.25 [1.03, 1.46]).
- PCSK9抑制剂与更高的尿酸盐水平有遗传联系 (IVW: OR 1.06 [1.01, 1.10]).
- 没有发现NPC1L1抑制剂与尿酸盐或痛风有显著的遗传关联;SMR分析没有证实任何目标的显著联系.
结论:
- 提供了新的遗传证据,证明了降脂药物标和痛风/尿酸水平之间的因果关系.
- HMGCR抑制剂可能会增加痛风风险,PCSK9抑制剂可能会增加尿酸盐度.
- 这些发现突出了降脂药物类别对代谢和炎症状况的潜在差异性影响.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
517
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
517
Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
Antihypertensive Drugs: Direct Renin Inhibitors
474
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
474
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Combined Effects of Drugs: Antagonism
8.2K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.2K
Antihypertensive Drugs: Thiazide-Class Diuretics
523
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
523


